Navigation Links
Good Samaritan Hospital-Dayton Rated #1 in Ohio for Vascular Surgery; #1 in Dayton for Joint Replacement
Date:10/13/2009

DAYTON, Ohio, Oct. 13 /PRNewswire/ -- Good Samaritan Hospital today announced that it has been rated number one in Ohio for vascular surgery and best in Dayton for joint replacement surgery by HealthGrades, the leading independent healthcare ratings organization.

The hospital also was recognized for its top national rankings for clinical quality with five-star ratings in nine categories. The recognition is based on HealthGrades' twelfth annual Hospital Quality in America study, released today, which analyzes patient outcomes at virtually all of the nation's hospitals.

"Our focus on high-quality, compassionate care is delivering nationally recognized results. Our HealthGrades ratings are a reflection of the dedication of our employees and medical staff -- we are all proud to receive such high ratings for our services," said Mark Shaker, president and CEO of Good Samaritan Hospital. "Especially with the recent opening of Dayton Heart & Vascular Hospital at Good Samaritan, we are thrilled to be recognized as number one in vascular surgery for the entire State of Ohio."

In the 2010 HealthGrades ratings, specific highlights for Good Samaritan include:

  • Ranked #1 in Ohio and Five-Star Rated for Vascular Surgery
  • Ranked Best in the Dayton Area and Five-Star Rated for Joint Replacement Surgery
  • Recipient of the following 2010 HealthGrades Specialty Excellence Awards:
    • Vascular Surgery
    • Pulmonary Care
    • Critical Care
  • Five-Star Rated for:
    • Total Knee Replacement Surgery
    • Carotid Surgery
    • Peripheral Vascular Bypass
    • Overall Pulmonary Services
    • Treatment of Heart Attack
    • Treatment of Heart Failure
    • Treatment of Pneumonia
    • Treatment of Respiratory Failure
    • Treatment of Sepsis

The HealthGrades study, the largest annual report of its kind, anal
'/>"/>

SOURCE Good Samaritan Hospital
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine news :

1. American Stock Exchange LLC to Delist Securities of Samaritan Pharmaceuticals, Inc.
2. CVS Samaritan Van Program Celebrates 30 Years of Helping Motorists on the Nations Highways
3. MedCath Enters Definitive Agreement to Sell Dayton Heart Hospital to Good Samaritan Hospital-Dayton
4. MedCath Announces Completion of Sale of Dayton Heart Hospital to Good Samaritan Hospital-Dayton
5. New York-Based Sanders Law Firm Files Claim for Good Samaritan Beaten by New York City Police Officers
6. The SCOOTER Store Gives Power Wheelchair to Good Samaritan Critically Injured Trying to Save Others
7. Good Samaritan Hospital-Dayton Hosts Local Students to Explore Health Careers, Learn Human Anatomy
8. Doctors at Banner Good Samaritan Medical Center Now Offering Precise Image-Guided Radiosurgery for Cancer and Neurological Disorders
9. Saturated Fat: Even a Little Splurge May Be Too Much
10. Health Integrated to Showcase Synergy Personal Health Management(R) at DMAA Conference
11. On 30th Anniversary, Angioplasty Celebrated as Modern Medical Breakthrough in Stopping Heart Attack
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... the April issue of Immunity , Kevin J. ... Research, says it,s time to take a fresh look ... sepsis, which kills millions worldwide every year, including more ... into the bloodstream to fight an injury or infection ... maintaining good health without inflammation, wounds and infections ...
(Date:4/17/2014)... biology team has created a new technology for ... could travel the body and selectively target cancer ... biological devices that monitor and modify human physiology ... However, no existing technology enabled bioengineers to build ... and respond in a customized fashion. , "The ...
(Date:4/17/2014)... MAYWOOD, Il. (April 17, 2014) Doctors who ... disease called lymphangioleiomyomatosis (LAM) can face an agonizing ... progression of the disease and help relieve shortness ... lung transplants, and sirolimus can cause potentially fatal ... said pulmonologist Dr. Daniel Dilling, medical director of ...
(Date:4/17/2014)... YORK, NY (April 16, 2014) The cause of ... a new study proposes that neurons may be mistaken ... immune system, similar to the way autoimmune diseases like ... the body,s cells. The study was published April 16, ... a new, and likely controversial, idea in Parkinson,s disease; ...
(Date:4/17/2014)... April 17, 2014 By discovering a new mechanism ... a stroke, researchers at UC Irvine and the Salk ... may limit or prevent stroke-induced brain damage. , A ... cause of death and primary reason for disability in ... a stroke and lets blood-borne material into the brain, ...
Breaking Medicine News(10 mins):Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Building 'smart' cell-based therapies 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Is Parkinson's an autoimmune disease? 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2
... ... Gary S. Berger MD today reported the results of the largest ... prospective study concludes that tubal ligation reversal is more successful than IVF ... of the study interval, over 60 percent of the tubal reversal patients ...
... ... supplier, Dynamic Computer Corporation, partners with AiRISTA to provide Wi-Fi-based RFID solutions. ... Sparks, ... agreement with Dynamic Computer Corporation (DCC) to promote, distribute, implement and support AiRISTA,s ...
... patient,s likelihood of survival. That is the finding of ... of Cancer , a peer-reviewed journal of the ... systematic screening of psychological distress and subsequent treatments. ... attitudes can impact their physical health. To determine the ...
... than standard medicines , SUNDAY, Sept. 13 (HealthDay News) ... pressure cannot be controlled by existing medications has done ... reductions in blood pressure were achieved with various doses ... hypertensive despite trying three or more medications, said a ...
... YORK, NY, Sept. 13 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - ... acquires, and develops novel drug targets that disrupt the ... appointed Dr. Philip Gould as a Member Designate of ... contribute his career experience in multinational blue chip drug ...
... ... High Point Solutions has been awarded the prestigious Gold certification from ... and specialization. The Certification recognizes High Point,s expert level of ... Unified Communication, and Data Center. Gold Certified Partners are considered extensions ...
Cached Medicine News:Health News:Study Shows Tubal Reversal Surgery is the Best Treatment to Have More Children After a Tubal Ligation 2Health News:AiRISTA's Unified Visibility Solutions Bringing Together Wi-Fi RTLS, And Telemetry Offer Enormous Business Opportunities To Systems Integrators 2Health News:Depression increases cancer patients' risk of dying 2Health News:Drug Offers Hope Against Tough-to-Treat Hypertension 2Health News:Drug Offers Hope Against Tough-to-Treat Hypertension 3Health News:GENova appoints Dr. Philip Gould to Scientific Advisory Board 2Health News:GENova appoints Dr. Philip Gould to Scientific Advisory Board 3Health News:High Point Solutions has Been Awarded the Prestigious Gold Certification from Cisco Systems 2
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... report is available in its catalogue: ... and Technologies for Advanced Drug Delivery ... Administration http://www.reportlinker.com/p01941928/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-Routes-of-Administration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ...
(Date:1/15/2014)...  A novel wearable injector slightly larger than an Oreo cookie ... self-inject prescription drugs in the large doses required to treat ... deficiencies, and genetic disorders.  An emerging biologic ... according to analysts.   Many of these drugs will require a ...
(Date:1/14/2014)...  Luminex Corporation (Nasdaq: LMNX ) today announced that ... 2013 on Monday, February 3, 2014. A press release announcing ... trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... highlights and financial results for the fourth quarter and twelve ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... WIRE via COMTEX News Network),-- Endo Pharmaceuticals ... Holdings Inc. (NASDAQ: ENDP), has presented results,from ... evaluating Frova (frovatriptan succinate) 2.5 mg,tablets as ... menstrual migraine (MM). The data demonstrated,that FROVA ...
... SALT LAKE CITY, UT, June 11, 2007 ... Genetics, Inc. (NASDAQ: MYGN) (<a target=,"_blank" href="http://www.myriad.com/">www.myriad.com ... comparison of a,"Staggered Start" and a "Randomized ... Staggered Start" clinical trial,design at the Alzheimer's ...
Cached Medicine Technology:Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 2Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 3Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 4Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 5Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 6Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 7Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 2Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 3Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 4Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 5
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: